These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 17163814)

  • 1. Molecular detection of tyrosinase transcripts in peripheral blood from patients with malignant melanoma: correlation of PCR sensitivity threshold with clinical and pathologic disease characteristics.
    Mitropapas G; Nezos A; Halapas A; Pissimissis N; Lembessis P; Sourla A; Vassilopoulos P; Koutsilieris M
    Clin Chem Lab Med; 2006; 44(12):1403-9. PubMed ID: 17163814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peripheral blood tyrosinase messenger RNA detection and survival in malignant melanoma.
    Kunter U; Buer J; Probst M; Duensing S; Dallmann I; Grosse J; Kirchner H; Schluepen EM; Volkenandt M; Ganser A; Atzpodien J
    J Natl Cancer Inst; 1996 May; 88(9):590-4. PubMed ID: 8609659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of tyrosinase mRNA from the blood of melanoma patients.
    Stevens GL; Scheer WD; Levine EA
    Cancer Epidemiol Biomarkers Prev; 1996 Apr; 5(4):293-6. PubMed ID: 8722221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of peripheral blood and bone marrow tyrosinase messenger RNA in malignant melanoma.
    Ghossein RA; Coit D; Brennan M; Zhang ZF; Wang Y; Bhattacharya S; Houghton A; Rosai J
    Clin Cancer Res; 1998 Feb; 4(2):419-28. PubMed ID: 9516931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reproducibility of detection of tyrosinase and MART-1 transcripts in the peripheral blood of melanoma patients: a quality control study using real-time quantitative RT-PCR.
    de Vries TJ; Fourkour A; Punt CJ; van de Locht LT; Wobbes T; van den Bosch S; de Rooij MJ; Mensink EJ; Ruiter DJ; van Muijen GN
    Br J Cancer; 1999 May; 80(5-6):883-91. PubMed ID: 10360670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RT-PCR for tyrosinase-mRNA-positive cells in peripheral blood: evaluation strategy and correlation with known prognostic markers in 123 melanoma patients.
    Farthmann B; Eberle J; Krasagakis K; Gstöttner M; Wang N; Bisson S; Orfanos CE
    J Invest Dermatol; 1998 Mar; 110(3):263-7. PubMed ID: 9506446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tyrosinase mRNA levels in the blood of uveal melanoma patients: correlation with the number of circulating tumor cells and tumor progression.
    Pinzani P; Mazzini C; Salvianti F; Massi D; Grifoni R; Paoletti C; Ucci F; Molinara E; Orlando C; Pazzagli M; Neri B
    Melanoma Res; 2010 Aug; 20(4):303-10. PubMed ID: 20442676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of melanoma cells in the blood of melanoma patients by melanoma-inhibitory activity (MIA) reverse transcription-PCR.
    Mühlbauer M; Langenbach N; Stolz W; Hein R; Landthaler M; Buettner R; Bosserhoff AK
    Clin Cancer Res; 1999 May; 5(5):1099-105. PubMed ID: 10353744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison between three molecular methods for detection of blood melanoma tyrosinase mRNA. Correlation with melanoma stages and S100B, LDH, NSE biochemical markers.
    Santonocito C; Concolino P; Lavieri MM; Ameglio F; Gentileschi S; Capizzi R; Rocchetti S; Amerio P; Castagnola M; Zuppi C; Capoluongo E
    Clin Chim Acta; 2005 Dec; 362(1-2):85-93. PubMed ID: 16054123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of positive RT-PCR for tyrosinase in peripheral blood of malignant melanoma patients with clinical stage, survival and other risk factors.
    Proebstle TM; Jiang W; Högel J; Keilholz U; Weber L; Voit C
    Br J Cancer; 2000 Jan; 82(1):118-23. PubMed ID: 10638977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The detection of tyrosinase mRNA in the peripheral blood of stage I melanoma patients is not of clinical relevance in predicting metastasis risk and survival.
    Aubin F; Chtourou M; Teyssier JR; Laubriet A; Mougin CH; Blanc D; Humbert P
    Melanoma Res; 2000 Apr; 10(2):113-8. PubMed ID: 10803711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathologic assessment of melanoma sentinel nodes: a role for molecular analysis using quantitative real-time reverse transcription-PCR for MART-1 and tyrosinase messenger RNA.
    Abrahamsen HN; Sorensen BS; Nexo E; Hamilton-Dutoit SJ; Larsen J; Steiniche T
    Clin Cancer Res; 2005 Feb; 11(4):1425-33. PubMed ID: 15746042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of tyrosinase mRNA as a tumor marker in the blood of melanoma patients.
    Jung FA; Buzaid AC; Ross MI; Woods KV; Lee JJ; Albitar M; Grimm EA
    J Clin Oncol; 1997 Aug; 15(8):2826-31. PubMed ID: 9256125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimization of the tyrosinase mRNA probe to detect circulating melanocytes with reverse transcription and polymerase chain reaction.
    Carrillo E; Marchal JA; Prados J; Melguizo C; Vélez C; Arena N; Alvarez L; Serrano S; Aránega A
    Cell Mol Biol (Noisy-le-grand); 1998 Dec; 44(8):1247-52. PubMed ID: 9874512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of melanoma cells in peripheral blood by reverse transcription-polymerase chain reaction for tyrosinase and MART-1 after mononuclear cell collection with cell preparation tubes: a comparison with the whole blood guanidinium isothiocyanate RNA isolation method.
    de Vries TJ; Fourkour A; Punt CJ; Ruiter DJ; van Muijen GN
    Melanoma Res; 2000 Apr; 10(2):119-26. PubMed ID: 10803712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multimarker real-time reverse transcription-PCR for quantitative detection of melanoma-associated antigens: a novel possible staging method.
    Arenberger P; Arenbergerova M; Gkalpakiotis S; Lippert J; Stribrna J; Kremen J
    J Eur Acad Dermatol Venereol; 2008 Jan; 22(1):56-64. PubMed ID: 18181974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Facts and pitfalls in the detection of tyrosinase mRNA in the blood of melanoma patients by RT-PCR.
    Seiter S; Rappl G; Tilgen W; Ugurel S; Reinhold U
    Recent Results Cancer Res; 2001; 158():105-12. PubMed ID: 11092037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular staging in stage II and III melanoma patients and its effect on long-term survival.
    Voit C; Kron M; Rademaker J; Schwürzer-Voit M; Sterry W; Weber L; Ozdemir C; Proebstle T; Keilholz U
    J Clin Oncol; 2005 Feb; 23(6):1218-27. PubMed ID: 15718319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic role of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction for tyrosinase mRNA in patients with melanoma.
    Visús C; Andres R; Mayordomo JI; Martinez-Lorenzo MJ; Murillo L; Sáez-Gutiérrez B; Diestre C; Marcos I; Astier P; Godino J; Carapeto-Marquez de Prado FJ; Larrad L; Tres A
    Melanoma Res; 2007 Apr; 17(2):83-9. PubMed ID: 17496783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of tyrosinase mRNA by an optimised nested RT-PCR in the peripheral blood of patients with advanced malignant melanoma.
    Glumac N; Hocevar M; Snoj M; Novakovic S
    J Exp Clin Cancer Res; 2001 Dec; 20(4):529-36. PubMed ID: 11876547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.